These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 18028082)

  • 1. Safety of i.v. administration of redback spider antivenom.
    Isbister GK
    Intern Med J; 2007 Dec; 37(12):820-2. PubMed ID: 18028082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antivenom use in Australia. Premedication, adverse reactions and the use of venom detection kits.
    Sutherland SK
    Med J Aust; 1992 Dec 7-21; 157(11-12):734-9. PubMed ID: 1360618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of serum antivenom concentrations after intravenous and intramuscular administration of redback (widow) spider antivenom.
    Isbister GK; O'Leary M; Miller M; Brown SG; Ramasamy S; James R; Schneider JS
    Br J Clin Pharmacol; 2008 Jan; 65(1):139-43. PubMed ID: 18171334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised controlled trial of intramuscular vs. intravenous antivenom for latrodectism--the RAVE study.
    Isbister GK; Brown SG; Miller M; Tankel A; Macdonald E; Stokes B; Ellis R; Nagree Y; Wilkes GJ; James R; Short A; Holdgate A
    QJM; 2008 Jul; 101(7):557-65. PubMed ID: 18400776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute hypersensitivity reactions associated with administration of crotalidae polyvalent immune Fab antivenom.
    Cannon R; Ruha AM; Kashani J
    Ann Emerg Med; 2008 Apr; 51(4):407-11. PubMed ID: 18191286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immediate hypersensitivity reactions after intravenous use of antivenin sera: prognostic value of intradermal sensitivity tests].
    Cupo P; Azevedo-Marques MM; de Menezes JB; Hering SE
    Rev Inst Med Trop Sao Paulo; 1991; 33(2):115-22. PubMed ID: 1844380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, randomized trial of intravenous versus intramuscular antivenom for red-back spider envenoming.
    Ellis RM; Sprivulis PC; Jelinek GA; Banham ND; Wood SV; Wilkes GJ; Siegmund A; Roberts BL
    Emerg Med Australas; 2005 Apr; 17(2):152-6. PubMed ID: 15796730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution in the choice of therapies used to treat latrodectism: Redback spider antivenom or standard analgesic medications. Nothing to rave about.
    Sulaeman SJ; Graudins A
    Emerg Med Australas; 2023 Aug; 35(4):630-635. PubMed ID: 36807536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Latrodectism: a prospective cohort study of bites by formally identified redback spiders.
    Isbister GK; Gray MR
    Med J Aust; 2003 Jul; 179(2):88-91. PubMed ID: 12864719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized controlled trial of intravenous antivenom versus placebo for latrodectism: the second Redback Antivenom Evaluation (RAVE-II) study.
    Isbister GK; Page CB; Buckley NA; Fatovich DM; Pascu O; MacDonald SP; Calver LA; Brown SG;
    Ann Emerg Med; 2014 Dec; 64(6):620-8.e2. PubMed ID: 24999282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spider bite--the redback spider and its relatives.
    Nimorakiotakis B; Winkel KD
    Aust Fam Physician; 2004 Mar; 33(3):153-7. PubMed ID: 15054982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of immediate and delayed hypersensitivity to Centruroides antivenom.
    LoVecchio F; Welch S; Klemens J; Curry SC; Thomas R
    Ann Emerg Med; 1999 Nov; 34(5):615-9. PubMed ID: 10533009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Examination of adverse events following black widow antivenom use in California.
    Nordt SP; Clark RF; Lee A; Berk K; Lee Cantrell F
    Clin Toxicol (Phila); 2012 Jan; 50(1):70-3. PubMed ID: 22175789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antivenom use, premedication and early adverse reactions in the management of snake bites in rural Papua New Guinea.
    Williams DJ; Jensen SD; Nimorakiotakis B; Müller R; Winkel KD
    Toxicon; 2007 May; 49(6):780-92. PubMed ID: 17210167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Route of administration of redback spider bite antivenom: determining clinician beliefs to facilitate Bayesian analysis of a clinical trial.
    Brown SG; Isbister GK; Stokes B
    Emerg Med Australas; 2007 Oct; 19(5):458-63. PubMed ID: 17919219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety profile of snake antivenom (use) in Hong Kong - a review of 191 cases from 2008 to 2015.
    Mong R; Ng VCH; Tse ML
    Clin Toxicol (Phila); 2017 Dec; 55(10):1066-1071. PubMed ID: 28657429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic antivenom and skin necrosis after green pit viper bites.
    Chotenimitkhun R; Rojnuckarin P
    Clin Toxicol (Phila); 2008 Feb; 46(2):122-5. PubMed ID: 18259959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Australian red-back spider (Latrodectus hasselti) antivenom in the treatment of clinical envenomation by the cupboard spider Steatoda capensis (Theridiidae).
    Atakuziev BU; Wright CE; Graudins A; Nicholson GM; Winkel KD
    Toxicon; 2014 Aug; 86():68-78. PubMed ID: 24853919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apparent marked reduction in early antivenom reactions compared to historical controls: was it prophylaxis or method of administration?
    Caron EJ; Manock SR; Maudlin J; Koleski J; Theakston RD; Warrell DA; Smalligan RD
    Toxicon; 2009 Nov; 54(6):779-83. PubMed ID: 19520099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High rate of immediate systemic hypersensitivity reactions to tiger snake antivenom. Comment.
    Leong J
    Med J Aust; 2006 Apr; 184(8):420. PubMed ID: 16646159
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.